Sale

Von Willebrand Disease Treatment Market

Global Von Willebrand Disease Treatment Market Size, Growth: By Disease Type: Type 1, Type 2, Type 3, Acquired VWD; By Drug: Desmopressin, Clot-stabilizing Medications, Replacement Therapies, Others; By Route of Administration: Oral, Injection, Others; Regional Analysis; Market Dynamics: SWOT Analysis; Competitive Landscape; 2024-2032

Global Von Willebrand Disease (VWD) Treatment Market Outlook

The global Von Willebrand disease (VWD) treatment market is expected to grow at a CAGR of 7.3% over the forecast period of 2024-2032. Several manufacturers have launched awareness programmes and patient aid programmes that will boost the demand for the therapy over the next few years.

 

Von Willebrand Disease Treatment Market

 Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Segmentation

For a patient suffering from Von Willebrand disease, an accident, a cut, or a surgery may lead to bleeding that is difficult to prevent. VWD is the most prevalent bleeding disorder. The global Von Willebrand disease (VWD) treatment market can be divided on the basis of segments like disease type, drug, route of administration, and gender.

 

Von Willebrand Disease (VWD) Treatment Market By Segments

 Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The industry can be divided on the basis of disease type into type 1 VWD, type 2 VWD, type 3 VWD, and acquired VWD. The industry can be segmented based on drug types into desmopressin, clot-stabilising medications, replacement therapies, and contraceptives, among others. The industry can be broadly categorised on the basis of the route of administration into:

  • Oral
  • Injection
  • Others

The industry can be bifurcated based on gender into men and women. The EMR report looks into the regional Von Willebrand disease treatment markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Market Analysis

The global Von Willebrand disease (VWD) treatment market is being driven by the rising incidence of bleeding disorders and increasing investment by companies in the R&D sector. Continued attempts to combat the disease, which is common among geriatric patients, and growing initiatives to develop orphan drugs, combined with ongoing technological advances, are further expected to fuel the growth of the Von Willebrand disease (VWD) treatment market.

 

Von Willebrand Disease (VWD) Treatment Market By Region

 Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global Von Willebrand disease (VWD) treatment market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • CSL Behring
  • Pfizer, Inc.  
  • Ferring Pharmaceuticals
  • Grifols, S.A.  
  • Octapharma AG    
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s five forces.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Disease Type
  • Drug
  • Route of Administration
  • Region
Breakup by Disease Type
  • Type 1 
  • Type 2 
  • Type 3 
  • Acquired VWD
Breakup by Drug
  • Desmopressin
  • Clot-stabilizing Medications
  • Replacement Therapies
  • Others
Breakup by Route of Administration
  • Oral
  • Injection
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • CSL Behring
  • Pfizer, Inc.  
  • Ferring Pharmaceuticals
  • Grifols, S.A.  
  • Octapharma AG    
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Opportunities and Challenges in the Market
8    Global Von Willebrand Disease Treatment Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Von Willebrand Disease Treatment Historical Market (2018-2023) 
    8.3    Global Von Willebrand Disease Treatment Market Forecast (2024-2032)
    8.4    Global Von Willebrand Disease Treatment Market by Disease Type
        8.4.1    Type 1 
            8.4.1.1    Historical Trend (2018-2023)
            8.4.1.2    Forecast Trend (2024-2032)
        8.4.2    Type 2 
            8.4.2.1    Historical Trend (2018-2023)
            8.4.2.2    Forecast Trend (2024-2032)
        8.4.3    Type 3 
            8.4.3.1    Historical Trend (2018-2023)
            8.4.3.2    Forecast Trend (2024-2032)
        8.4.4    Acquired VWD
            8.4.4.1    Historical Trend (2018-2023)
            8.4.4.2    Forecast Trend (2024-2032)
    8.5    Global Von Willebrand Disease Treatment Market by Drug
        8.5.1    Desmopressin
            8.5.1.1    Historical Trend (2018-2023)
            8.5.1.2    Forecast Trend (2024-2032)
        8.5.2    Clot-stabilizing Medications
            8.5.2.1    Historical Trend (2018-2023)
            8.5.2.2    Forecast Trend (2024-2032)
        8.5.3    Replacement Therapies  
            8.5.3.1    Historical Trend (2018-2023)
            8.5.3.2    Forecast Trend (2024-2032)
        8.5.4    Others
    8.6    Global Von Willebrand Disease Treatment Market by Route of Administration
        8.6.1    Oral
            8.6.1.1    Historical Trend (2018-2023)
            8.6.1.2    Forecast Trend (2024-2032)
        8.6.2    Injection
            8.6.2.1    Historical Trend (2018-2023)
            8.6.2.2    Forecast Trend (2024-2032)
        8.6.3    Others   
    8.7    Global Von Willebrand Disease Treatment Market by Region
        8.7.1    North America
            8.7.1.1    Historical Trend (2018-2023) 
            8.7.1.2    Forecast Trend (2024-2032)
        8.7.2    Europe
            8.7.2.1    Historical Trend (2018-2023) 
            8.7.2.2    Forecast Trend (2024-2032)
        8.7.3    Asia Pacific
            8.7.3.1    Historical Trend (2018-2023) 
            8.7.3.2    Forecast Trend (2024-2032)
        8.7.4    Latin America
            8.7.4.1    Historical Trend (2018-2023) 
            8.7.4.2    Forecast Trend (2024-2032)
        8.7.5    Middle East and Africa
            8.7.5.1    Historical Trend (2018-2023) 
            8.7.5.2    Forecast Trend (2024-2032)
9    North America Von Willebrand Disease Treatment Market Analysis
    9.1    United States of America 
        9.1.1    Historical Trend (2018-2023) 
        9.1.2    Forecast Trend (2024-2032)
    9.2    Canada
        9.2.1    Historical Trend (2018-2023) 
        9.2.2    Forecast Trend (2024-2032)
10    Europe Von Willebrand Disease Treatment Market Analysis
    10.1    United Kingdom
        10.1.1    Historical Trend (2018-2023) 
        10.1.2    Forecast Trend (2024-2032)
    10.2    Germany
        10.2.1    Historical Trend (2018-2023) 
        10.2.2    Forecast Trend (2024-2032)
    10.3    France
        10.3.1    Historical Trend (2018-2023) 
        10.3.2    Forecast Trend (2024-2032)
    10.4    Italy
        10.4.1    Historical Trend (2018-2023) 
        10.4.2    Forecast Trend (2024-2032)
    10.5   Others
11    Asia Pacific Von Willebrand Disease Treatment Market Analysis
    11.1    China
        11.1.1    Historical Trend (2018-2023) 
        11.1.2    Forecast Trend (2024-2032)
    11.2    Japan
        11.2.1    Historical Trend (2018-2023) 
        11.2.2    Forecast Trend (2024-2032)
    11.3    India
        11.3.1    Historical Trend (2018-2023) 
        11.3.2    Forecast Trend (2024-2032)
    11.4    ASEAN
        11.4.1    Historical Trend (2018-2023) 
        11.4.2    Forecast Trend (2024-2032)
    11.5    Australia
        11.5.1    Historical Trend (2018-2023) 
        11.5.2    Forecast Trend (2024-2032)
    11.6    Others
12    Latin America Von Willebrand Disease Treatment Market Analysis
    12.1    Brazil
        12.1.1    Historical Trend (2018-2023) 
        12.1.2    Forecast Trend (2024-2032)
    12.2    Argentina
        12.2.1    Historical Trend (2018-2023) 
        12.2.2    Forecast Trend (2024-2032)
    12.3    Mexico
        12.3.1    Historical Trend (2018-2023) 
        12.3.2    Forecast Trend (2024-2032)
    12.4    Others
13    Middle East and Africa Von Willebrand Disease Treatment Market Analysis
    13.1    Saudi Arabia
        13.1.1    Historical Trend (2018-2023) 
        13.1.2    Forecast Trend (2024-2032)
    13.2    United Arab Emirates
        13.2.1    Historical Trend (2018-2023) 
        13.2.2    Forecast Trend (2024-2032)
    13.3    Nigeria
        13.3.1    Historical Trend (2018-2023) 
        13.3.2    Forecast Trend (2024-2032)
    13.4    South Africa
        13.4.1    Historical Trend (2018-2023) 
        13.4.2    Forecast Trend (2024-2032)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Competitive Landscape
    15.1    Market Structure
    15.2    Company Profiles
        15.2.1    CSL Behring
            15.2.1.1    Company Overview
            15.2.1.2    Product Portfolio
            15.2.1.3    Demographic Reach and Achievements
            15.2.1.4    Certifications
        15.2.2    Pfizer, Inc.
            15.2.2.1    Company Overview
            15.2.2.2    Product Portfolio
            15.2.2.3    Demographic Reach and Achievements
            15.2.2.4    Certifications
        15.2.3    Ferring Pharmaceuticals
            15.2.3.1    Company Overview
            15.2.3.2    Product Portfolio
            15.2.3.3    Demographic Reach and Achievements
            15.2.3.4    Certifications
        15.2.4    Grifols, S.A.
            15.2.4.1    Company Overview
            15.2.4.2    Product Portfolio
            15.2.4.3    Demographic Reach and Achievements
            15.2.4.4    Certifications
        15.2.5    Octapharma AG
            15.2.5.1    Company Overview
            15.2.5.2    Product Portfolio
            15.2.5.3    Demographic Reach and Achievements
            15.2.5.4    Certifications
        15.2.6    Sanofi S.A.
            15.2.6.1    Company Overview
            15.2.6.2    Product Portfolio
            15.2.6.3    Demographic Reach and Achievements
            15.2.6.4    Certifications
        15.2.7    Sun Pharmaceutical Industries Ltd.
            15.2.7.1    Company Overview
            15.2.7.2    Product Portfolio
            15.2.7.3    Demographic Reach and Achievements
            15.2.7.4    Certifications
        15.2.8    Others
16    Key Trends and Developments in the Market


List of Key Figures and Tables

1.    Global Von Willebrand Disease Treatment Market: Key Industry Highlights, 2018 and 2032
2.    Global Von Willebrand Disease Treatment Historical Market: Breakup by Disease Type (USD Million), 2018-2023
3.    Global Von Willebrand Disease Treatment Market Forecast: Breakup by Disease Type (USD Million), 2024-2032
4.    Global Von Willebrand Disease Treatment Historical Market: Breakup by Drug (USD Million), 2018-2023
5.    Global Von Willebrand Disease Treatment Market Forecast: Breakup by Drug (USD Million), 2024-2032
6.    Global Von Willebrand Disease Treatment Historical Market: Breakup by Gender (USD Million), 2018-2023
7.    Global Von Willebrand Disease Treatment Market Forecast: Breakup by Gender (USD Million), 2024-2032
8.    Global Von Willebrand Disease Treatment Historical Market: Breakup by Route of Administration (USD Million), 2018-2023
9.    Global Von Willebrand Disease Treatment Market Forecast: Breakup by Route of Administration (USD Million), 2024-2032
10.    Global Von Willebrand Disease Treatment Historical Market: Breakup by Region (USD Million), 2018-2023
11.    Global Von Willebrand Disease Treatment Market Forecast: Breakup by Region (USD Million), 2024-2032
12.    North America Von Willebrand Disease Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
13.    North America Von Willebrand Disease Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
14.    Europe Von Willebrand Disease Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
15.    Europe Von Willebrand Disease Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
16.    Asia Pacific Von Willebrand Disease Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
17.    Asia Pacific Von Willebrand Disease Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
18.    Latin America Von Willebrand Disease Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
19.    Latin America Von Willebrand Disease Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
20.    Middle East and Africa Von Willebrand Disease Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
21.    Middle East and Africa Von Willebrand Disease Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
22.    Global Von Willebrand Disease Treatment Market Structure

Key Questions Answered in the Report

The global Von Willebrand disease (VWD) treatment market is projected to grow at a CAGR of 7.3% between 2024 and 2032.

The market is being driven by the increasing incidences of bleeding disorders, the growing geriatric population, and the rising initiatives to develop orphan drugs.

The market growth in the forecast period can be associated with the rising launches of awareness programmes, the growing R&D activities, and the increasing new product launches.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The major disease types of Von Willebrand disease (VWD) treatment are type 1, type 2, type 3, and acquired VWD.

The various drugs of  Von Willebrand disease (VWD) treatment are desmopressin, clot-stabilising medications, and replacement therapies, among others.

The significant routes of administration of  Von Willebrand disease (VWD) treatment include oral and injection, among others.

The major players in the industry are CSL Behring, Pfizer Inc., Octapharma AG, Ferring Pharmaceuticals, Grifols, S.A., Octapharma AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Others.

Analyst Review

The global Von Willebrand disease (VWD) treatment market is driven by the increasing incidences of bleeding disorders. Aided by the growing awareness regarding the significance of optimal treatment of Von Willebrand disease (VWD), the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 7.3%.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on disease type, the Von Willebrand disease (VWD) treatment industry can be divided into type 1, type 2, type 3, and acquired VWD. By drug, the market can be classified into desmopressin, clot-stabilising medications, and replacement therapies, among others. On the basis of routes of administration, the market is classified into oral and injection, among others. The major regional markets for  Von Willebrand disease (VWD) treatment are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include CSL Behring, Pfizer Inc., Octapharma AG, Ferring Pharmaceuticals, Grifols, S.A., Octapharma AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER